Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

5.890
+0.0701.20%
Volume:126.58M
Turnover:724.44M
Market Cap:110.50B
PE:30.79
High:5.920
Open:5.820
Low:5.420
Close:5.820
52wk High:9.120
52wk Low:3.137
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:2.52
T/O Rate:0.67%
Dividend:0.09
Dividend Rate:1.59%
EPS(LYR):0.191
ROE:15.40%
ROA:5.07%
PB:2.93
PE(LYR):30.79
PS:3.19

Loading ...

Sino Biopharmaceutical Stock Climbs 3.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Mar 05

Hong Kong Healthcare Stocks Rebound Strongly: Innovative Drug ETF Surges Over 3%

Deep News
·
Mar 05

Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi

Stock Track
·
Mar 05

SINO BIOPHARM Shares Surge Over 5% on $1.53 Billion Licensing Deal with Sanofi for Rovadicitinib

Stock News
·
Mar 05

Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals

Dow Jones
·
Mar 04

Sino Biopharmaceutical Limited (1177) Announces Exclusive License Agreement with Sanofi

Bulletin Express
·
Mar 04

Sino Biopharm Inks Exclusive Licensing Deal with Sanofi for Rovadicitinib

Stock News
·
Mar 04

Sino Biopharmaceutical Licenses ROVADICITINIB to Sanofi in Exclusive Global Deal

Reuters
·
Mar 04

Sino Biopharmaceutical - Exclusive License Agreement for Rovadicitinib With Sanofi

THOMSON REUTERS
·
Mar 04

Sino Biopharmaceutical - Sales Milestone Payments of up to US$1,395 Mln

THOMSON REUTERS
·
Mar 04

Sino Biopharmaceutical - Group Is Eligible to Receive an Upfront Payment of US$135 Mln

THOMSON REUTERS
·
Mar 04

Sino Biopharmaceutical Stock Slips 2.8% in Hong Kong

Dow Jones
·
Mar 02

Sino Biopharmaceutical (01177) Publishes February 2026 Monthly Return, No Change to Issued Shares

Bulletin Express
·
Mar 02

Sino Biopharmaceutical Limited (1177) Announces Approval of Rovadicitinib Tablet

Bulletin Express
·
Mar 02

SINO BIOPHARM's Self-Developed Innovative Drug Rovaxicitinib Approved for Market Launch

Stock News
·
Mar 02

Sino Biopharmaceutical - Receives Nmpa Approval for Rovadicitinib Tablet

THOMSON REUTERS
·
Mar 02

China NMPA Approves Sino Biopharmaceutical’s Rovadicitinib Tablet for Marketing

Reuters
·
Mar 02

Sino Biopharmaceutical Stock Slides 3.8% in Hong Kong

Dow Jones
·
Feb 26

Transforming China's Biopharma Giant: The Xie Siblings' Strategic Capital Moves

Deep News
·
Feb 26

Sino Biopharmaceutical Stock Slides 6.6% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 24